Details

Autor(en) / Beteiligte

• Wang, Jayson
• Taylor, Alexandra
• Showeil, Rania
• Trivedi, Pritesh
• Horimoto, Yoshiya
• Bagwan, Izhar
• Ewington, Lauren
• Lam, Eric W.-F.
• El-Bahrawy, Mona A.

Titel

Expression profiling and significance of VEGF-A, VEGFR2, VEGFR3 and related proteins in endometrial carcinoma

Ist Teil von

• Cytokine (Philadelphia, Pa.), 2014-08, Vol.68 (2), p.94-100

Ort / Verlag

England: Elsevier Ltd

Erscheinungsjahr

2014

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• •Angiogenic factors, including the VEGF family play a role in tumor progression.•We show increased expression of VEGF-A, VEGFR2 and VEGFR3 in endometrial cancers.•VEGFR3 expression significantly correlates with tumor stage.•There are significant correlations in expression of VEGFR2 and 3, EGFR, CXCR1 and 2.•Cross-talk exists between angiogenic factors, and they may have a prognostic role. Angiogenesis plays a key role in the progression of various tumors, including endometrial carcinomas. Several cytokines and their associated receptors are shown to be involved, particularly VEGF-A with VEGFR1, -2 and -3. The expressions of VEGF-A, VEGFR2 and VEGFR3 were studied in by immunohistochemistry in 76 endometrial carcinoma specimens. VEGFR2 and VEGFR3 receptor expression were also studied by qRT-PCR in 17 tumors in comparison to normal endometrium. The expression profiles were correlated with tumor type, grade, stage, lymphovascular invasion, disease free survival, and the expressions of other cytokine receptors (EGFR, CXCR1 and CXCR2). Immunohistochemically, 63% of endometrial cancers expressed VEGF-A, 55% VEGFR2 and 26% VEGFR3. VEGFR3 was significantly correlated with tumor stage (p=0.02), with a trend towards poorer disease free survival (p=0.09). VEGF-A was significantly correlated with microvessel density (p<0.01). Using qRT-PCR, increased expression of VEGFR2 (17.2-fold) and VEGFR3 (21.9-fold) was seen in endometrial carcinomas compared with normal endometrium, with significant correlations among the expression levels of VEGFR2, VEGFR3, EGFR, CXCR1 and CXCR2. Our study suggests that evaluation of VEGFR3 expression in tumors may provide prognostic data, and help identify patients who would best benefit from anti-angiogenic therapeutic agents. This is the first report showing correlations between the expressions levels of the different receptors.